gemfibrozil has been researched along with HIV-Associated Lipodystrophy Syndrome in 1 studies
HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martínez, E | 1 |
| Domingo, P | 1 |
| Ribera, E | 1 |
| Milinkovic, A | 1 |
| Arroyo, JA | 1 |
| Conget, I | 1 |
| Pérez-Cuevas, JB | 1 |
| Casamitjana, R | 1 |
| de Lazzari, E | 1 |
| Bianchi, L | 1 |
| Montserrat, E | 1 |
| Roca, M | 1 |
| Burgos, R | 1 |
| Arnaiz, JA | 1 |
| Gatell, JM | 1 |
1 trial available for gemfibrozil and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Constitution; Double-Blind Method; Female; Gemfib | 2003 |